The post-market phase is the phase following the placement of medical devices on the market. ISO 14971 also refers to the post-production phase after development and production.
Content
This page provides a quick overview of the articles on the post-market phase:
The post-market or post-production phase comprises all activities after production until the decommissioning/decommissioning of the devices, at the latest, at the end of their service life. These activities also include use and maintenance.
Fig. 1: The post-market phase is an important part of the product life cycle.
The international regulatory requirements for the post-market phase are increasing. The EU MDR and IVDR regulations are evidence of this. In addition, there are national regulations, such as 21 CFR part 822 on post-market surveillance, and national laws and regulations on vigilance, such as the German law MPAIMV.
There are also guidelines, such as MDCG 2022-21 and MDCG 2020-6, and laws that apply to all devices, such as the Product Liability Act, which also requires post-market activities such as monitoring.
The regulations oblige manufacturers to carry out post-market surveillance, for example. To this end, manufacturers must draw up a post-market surveillance plan and collect and evaluate the post-market surveillance data in accordance with this plan. Manufacturers find it particularly difficult to analyze trends. The output then flows into reports such as the Periodic Safety Update Report (PSUR).
Depending on the class of the devices, the reports must also be published in EUDAMED.
One part of post-market surveillance is the post-market clinical follow-up (PMCF). This involves collecting clinical data to keep the clinical evaluation up to date. If the data is insufficient, PMCF studies may be necessary.
If serious incidents or trends leading to an unacceptable risk are observed in the post-market phase, manufacturers must notify the authorities (vigilance) and take corrective action.
Post-market activities include monitoring new regulations (regulatory update), monitoring vulnerabilities in off-the-shelf software, and eliminating these vulnerabilities with security patches.
These activities are not only the responsibility of manufacturers, for example, their product managers, quality management representatives, medical device consultants, and responsible persons.
Suppliers, importers, and distributors also have obligations in this post-production phase.
The essential objective of all these activities is to ensure patient safety, i.e., to minimize risks from unsafe devices.
For this reason, the third edition of the risk management standard ISO 14971 has increased the requirements for the post-production phase. The associated Technical Report ISO/TR 24971 describes these requirements in more detail.
To assess the benefit-risk ratio, manufacturers must continuously monitor and consider the state of the art.
Not doing so is one of the most common mistakes in risk management.
Do you still have questions about the post-market phase? Then, take advantage of our free micro-consulting.
If you want to delve deeper into the topic, we offer video training courses at the Medical Device University.
The post-market services take a large part of the work off your hands, from monitoring the regulations to post-market surveillance. This enables you to achieve:
Contact us if you would like support.
The risk management plan is one of the most important documents in technical documentation. Accordingly, authorities and notified bodies examine this plan intensively. However, it is not only from a regulatory perspective that medical device manufacturers benefit from a precise risk management plan. This article 1. What a risk management plan is In a risk…
DetailsHow to meet PMCF regulatory requirements as quickly as possible Post-Market Clinical Follow-up is increasingly being criticized by the notified bodies. And this is after the manufacturers have successfully mastered the hurdle before: the initial clinical evaluation. This article provides manufacturers of medical devices with 1. PMCF: The basics a) Objective and definition The MDR…
DetailsBoth the FDA and IEC 62304 recognize software developed by third parties. They refer to Off-the-Shelf Software (OTS) and Software Of Unknown Provenance (SOUP). What is the difference between OTS and SOUP? What do they have in common? What legal requirements do they have to meet? This article provides answers. 1. SOUP and OTS: definition…
DetailsOnly through clinical evidence – real evidence – can manufacturers prove their medical devices’ safety, performance, and benefit. But when is proof valid enough? In other words, when is there sufficient clinical evidence for authorities and notified bodies to accept? This article answers the questions and provides a compact introduction to the topic of “clinical…
DetailsEUDAMED is the European database for medical devices. However, it is not only used to manage medical devices. The Medical Device Regulation (MDR) relies on EUDAMED and determines which requirements must be stored in this database. These regulations affect the work of manufacturers and also the work of authorities and notified bodies. 1. Which purpose…
DetailsPMCF studies are studies that manufacturers use as part of Post-Market Clinical Follow-up (PMCF) to continuously demonstrate compliance of their medical devices. Manufacturers do not always need to conduct studies to meet PMCF requirements. And not all types of PMCF studies are subject to MDR requirements. This article compactly summarizes the regulatory requirements in the…
DetailsMedical device manufacturers have high expectations of Regulatory Information Management Systems (RIMS). The costs and efforts involved are immense and usually much higher than expected. The benefits, on the other hand, are not clear. This article will give you some hints, 1. Definition: RIMS 2. Goals of RIMS Pharmaceutical and medical device manufacturers expect several…
DetailsThe EU regulations the MDR and IVDR set out precise requirements for importers. And they also define who is an importer. Bringing a device into the EU does not always constitute an import. And, furthermore, companies that import medical devices don’t just have to meet the requirements established for importers. 1. What is an importer?…
DetailsMany companies consider Regulatory Intelligence so important that they create their own roles and departments for it. This article clarifies what Regulatory Intelligence is, how companies can benefit from it, and where tools can provide support. 1. What is “Regulatory Intelligence”? This includes gathering and analyzing regulatory information from various sources, including regulatory agencies, industry…
DetailsTrend analysis is a legal obligation of all medical device manufacturers, especially in “Post-Market Surveillance.” Manufacturers must not fail in the selection and application of suitable statistical methods for trend analysis. This is because the focus of authorities and notified bodies is increasingly shifting to monitoring post-market activities. This article provides a quick introduction to this…
Details